2024
Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?
Barnett B, Anand A, Dewey E, Smith D, Nayak S, Bruckman D, Weleff J. Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably? Psychedelic Medicine 2024, 2: 74-86. DOI: 10.1089/psymed.2023.0027.Peer-Reviewed Original ResearchNational Survey on Drug Use and HealthDrug Use and HealthLysergic acid diethylamideUnited StatesSurvey yearSexual minoritiesYear suicide attemptMale genderRespondents' ageScholarly workAcid diethylamideMultivariate modelRisk profileGenderPerceived riskHigher education levelProportion of respondentsEducation levelStatistically significant associationGeneral publicPsychological distressLSD use in the United States: Examining user demographics and their evolution from 2015–2019
Weleff J, Anand A, Dewey E, Barnett B. LSD use in the United States: Examining user demographics and their evolution from 2015–2019. Journal Of Psychedelic Studies 2024 DOI: 10.1556/2054.2024.00309.Peer-Reviewed Original ResearchLysergic acid diethylamideUnited StatesNational Survey on Drug Use and Health (NSDUHDrug Use and Health (NSDUHLysergic acid diethylamide useArrest historyHallucinogen use disordersLSD useUsers of methamphetaminePublic health problemMultivariate analysisLifetime usersUse disorderPast-year psychological distressAcid diethylamideProportion of respondentsPast-year suicide attemptStudy periodEpidemiological investigationsSocietal acceptanceSuicide attemptsLSD usersApplications of psychedelicsTherapeutic applicationsAssociated with unemployment
2023
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Kovacevich A, Weleff J, Claytor B, Barnett B. Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD. Journal Of Psychoactive Drugs 2023, 55: 672-679. PMID: 37650700, DOI: 10.1080/02791072.2023.2253538.Peer-Reviewed Original ResearchConceptsLysergic acid diethylamidePsychedelic useOlfactory impairmentOlfactory improvementClassic psychedelic useCOVID-19-related anosmiaSerotonergic effectsIncreased neuroplasticityAnti-inflammatory effectsNaturalistic useAcid diethylamideOlfactory dysfunctionMicrosmiaPsilocybinRespiratory infectionsPsilocybin mushroomsTherapeutic benefitAnosmiaNovel treatmentReport improvementImpairmentPotential mechanismsBiological plausibilityGrowing bodyWomen
2022
Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies
Weleff J, Akiki T, Barnett B. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies. Journal Of Psychoactive Drugs 2022, 55: 434-444. PMID: 36218281, DOI: 10.1080/02791072.2022.2133757.Peer-Reviewed Original ResearchLysergic acid diethylamidePsychedelic researchBibliometric analysisEffects of psychedelicsStudies of psychedelicsClinical psychedelic researchNon-research settingsPsychiatric treatmentN-dimethyltryptamineProportion of studiesAcid diethylamidePsilocybinPsychedelicsSubanalysis of studiesPsilocybin studiesDimethyltryptamineMDMARelevant articlesMescalinePsychedelics in the Treatment of Substance Use Disorders
Barnett B, Weleff J. Psychedelics in the Treatment of Substance Use Disorders. Psychiatric Annals 2022, 52: 365-370. DOI: 10.3928/00485713-20220804-01.Peer-Reviewed Original ResearchSubstance use disordersPsychedelic experienceTreatment of substance use disordersLysergic acid diethylamideSubjective effectsUse disorderAcid diethylamidePlacebo-controlled trialPsychedelicsBehavioral changesTherapeutic potentialClinician concernsLife narrativesDisordersFacilitation programTreatment paradigmTherapeutic efficacyClinical trialsTreatment potentialObservational studyPsilocybinDiethylamideTrialsSubstancesOpioid